JP2004525142A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004525142A5 JP2004525142A5 JP2002574985A JP2002574985A JP2004525142A5 JP 2004525142 A5 JP2004525142 A5 JP 2004525142A5 JP 2002574985 A JP2002574985 A JP 2002574985A JP 2002574985 A JP2002574985 A JP 2002574985A JP 2004525142 A5 JP2004525142 A5 JP 2004525142A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- pharmaceutical combination
- additional therapeutic
- formula
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 44
- 229940124597 therapeutic agent Drugs 0.000 claims 43
- 150000001875 compounds Chemical class 0.000 claims 27
- 238000000034 method Methods 0.000 claims 24
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 21
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 14
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 229940104302 cytosine Drugs 0.000 claims 11
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 10
- 229960000684 cytarabine Drugs 0.000 claims 10
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical group NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 8
- 229960004413 flucytosine Drugs 0.000 claims 8
- 229960005277 gemcitabine Drugs 0.000 claims 8
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 8
- 239000002777 nucleoside Substances 0.000 claims 8
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical group C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 7
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 7
- 239000002246 antineoplastic agent Substances 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 7
- 229940127089 cytotoxic agent Drugs 0.000 claims 7
- 239000001177 diphosphate Substances 0.000 claims 7
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 7
- 235000011180 diphosphates Nutrition 0.000 claims 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 7
- 229960000908 idarubicin Drugs 0.000 claims 7
- 150000004712 monophosphates Chemical class 0.000 claims 7
- 125000006239 protecting group Chemical group 0.000 claims 7
- 239000001226 triphosphate Substances 0.000 claims 7
- 235000011178 triphosphate Nutrition 0.000 claims 7
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 7
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 208000032839 leukemia Diseases 0.000 claims 5
- 230000002195 synergetic effect Effects 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 230000003796 beauty Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- -1 cytosine nucleoside Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000003835 nucleoside group Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27797501P | 2001-03-23 | 2001-03-23 | |
| US33060101P | 2001-10-25 | 2001-10-25 | |
| PCT/CA2002/000426 WO2002076472A2 (en) | 2001-03-23 | 2002-03-25 | Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004525142A JP2004525142A (ja) | 2004-08-19 |
| JP2004525142A5 true JP2004525142A5 (enExample) | 2005-12-22 |
| JP4391087B2 JP4391087B2 (ja) | 2009-12-24 |
Family
ID=26958821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002574985A Expired - Fee Related JP4391087B2 (ja) | 2001-03-23 | 2002-03-25 | 癌の処置のための薬学的組み合わせ |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6800639B2 (enExample) |
| EP (1) | EP1370270B1 (enExample) |
| JP (1) | JP4391087B2 (enExample) |
| KR (1) | KR20040018341A (enExample) |
| AT (1) | ATE450265T1 (enExample) |
| CA (1) | CA2441568A1 (enExample) |
| DE (1) | DE60234577D1 (enExample) |
| HU (1) | HUP0400314A3 (enExample) |
| MX (1) | MXPA03008623A (enExample) |
| NO (1) | NO20034204L (enExample) |
| NZ (1) | NZ528394A (enExample) |
| PL (1) | PL365285A1 (enExample) |
| WO (1) | WO2002076472A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US20080075762A1 (en) * | 2001-10-03 | 2008-03-27 | Paul Tardi | Compositions for delivery of drug combinations |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| WO2004012744A1 (de) * | 2002-07-30 | 2004-02-12 | Zentaris Gmbh | Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten |
| US8383605B2 (en) * | 2002-07-30 | 2013-02-26 | Aeterna Zentaris Gmbh | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals |
| US20040192652A1 (en) * | 2002-12-06 | 2004-09-30 | Giles Francis J. | Pharmaceutical combinations and methods for the treatment of leukemia |
| WO2004087094A2 (en) * | 2003-04-02 | 2004-10-14 | Celator Pharmaceuticals, Inc. | Nano-sized vehicles transporting a therapeutic agent and at least one drug resistance modulator for the treatment of multi drug resistance |
| BRPI0409133B8 (pt) | 2003-04-08 | 2021-05-25 | Progenics Pharm Inc | preparações farmacêuticas estavéis compreendendo metilnaltrexona |
| US20040248915A1 (en) * | 2003-04-25 | 2004-12-09 | Jacques Jolivet | Method for administration of troxacitabine |
| MXPA06003222A (es) * | 2003-09-25 | 2006-05-22 | Astellas Pharma Inc | Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii. |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| BRPI0608818A2 (pt) | 2005-03-07 | 2010-01-26 | Univ Chicago | uso de antagonista opióides para atenuação de proliferação e migração de células endoteliais |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| CN103028120B (zh) | 2005-09-12 | 2015-08-12 | 俄亥俄州立大学研究基金会 | 用于诊断或治疗bcl2相关癌症的组合物和方法 |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| CA2662147A1 (en) * | 2006-09-01 | 2008-03-13 | University Of Georgia Research Foundation, Inc. | L-oddc prodrugs for cancer |
| EP2134718A2 (en) | 2007-03-29 | 2009-12-23 | Progenics Pharmaceuticals, Inc. | Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof |
| PT2139890E (pt) | 2007-03-29 | 2014-09-03 | Wyeth Llc | Antagonistas do receptor opióide periférico e respectivas utilizações |
| CA2682125C (en) | 2007-03-29 | 2015-06-16 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
| US20090048205A1 (en) * | 2007-08-15 | 2009-02-19 | Colin Meyer | Combination therapy with synthetic triterpenoids and gemcitabine |
| LT2252283T (lt) | 2008-01-11 | 2019-03-25 | Reata Pharmaceuticals, Inc. | Sintetiniai triterpenoidai ir jų panaudojimo būdai gydant ligą |
| CA2713568C (en) | 2008-02-06 | 2016-09-20 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
| AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| US20100004193A1 (en) * | 2008-07-07 | 2010-01-07 | Fondazione Per La Ricerca Biomedica Avanzata Onlus - Istituto Veneto Di Medicina Molecolare | Combination therapy |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| WO2011123691A1 (en) | 2010-03-31 | 2011-10-06 | Keryx Biopharmaceuticals, Inc. | Perifosine and capecitabine as a combined treatment for cancer |
| MY163031A (en) * | 2010-04-12 | 2017-07-31 | Reata Pharmaceuticals Inc | Method of treating obesity using antioxidant inflammation modulators |
| US10613087B2 (en) * | 2012-08-10 | 2020-04-07 | Analiza, Inc. | Methods and devices for analyzing species to determine diseases |
| JP7337539B2 (ja) | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041449A (en) | 1988-04-11 | 1991-08-20 | Iaf Biochem International, Inc. | 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections |
| US6350753B1 (en) * | 1988-04-11 | 2002-02-26 | Biochem Pharma Inc. | 2-Substituted-4-substituted-1,3-dioxolanes and use thereof |
| US5270315A (en) | 1988-04-11 | 1993-12-14 | Biochem Pharma Inc. | 4-(purinyl bases)-substituted-1,3-dioxlanes |
| US5817667A (en) | 1991-04-17 | 1998-10-06 | University Of Georgia Research Foudation | Compounds and methods for the treatment of cancer |
| WO1992018517A1 (en) * | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
| IL115156A (en) * | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
| CN1297281C (zh) | 1999-03-29 | 2007-01-31 | 希拉生物化学股份有限公司 | 治疗白血病的方法 |
| AU2002212015B2 (en) * | 2000-10-13 | 2007-01-25 | Shire Canada Inc. | Dioxolane analogs for improved inter-cellular delivery |
| US20040248915A1 (en) * | 2003-04-25 | 2004-12-09 | Jacques Jolivet | Method for administration of troxacitabine |
-
2002
- 2002-03-25 HU HU0400314A patent/HUP0400314A3/hu unknown
- 2002-03-25 EP EP02713967A patent/EP1370270B1/en not_active Expired - Lifetime
- 2002-03-25 WO PCT/CA2002/000426 patent/WO2002076472A2/en not_active Ceased
- 2002-03-25 NZ NZ528394A patent/NZ528394A/en not_active IP Right Cessation
- 2002-03-25 AT AT02713967T patent/ATE450265T1/de not_active IP Right Cessation
- 2002-03-25 MX MXPA03008623A patent/MXPA03008623A/es active IP Right Grant
- 2002-03-25 KR KR10-2003-7012324A patent/KR20040018341A/ko not_active Withdrawn
- 2002-03-25 US US10/104,067 patent/US6800639B2/en not_active Expired - Lifetime
- 2002-03-25 CA CA002441568A patent/CA2441568A1/en not_active Abandoned
- 2002-03-25 PL PL02365285A patent/PL365285A1/xx unknown
- 2002-03-25 DE DE60234577T patent/DE60234577D1/de not_active Expired - Lifetime
- 2002-03-25 JP JP2002574985A patent/JP4391087B2/ja not_active Expired - Fee Related
-
2003
- 2003-09-22 NO NO20034204A patent/NO20034204L/no not_active Application Discontinuation
-
2004
- 2004-05-26 US US10/853,241 patent/US20050004081A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004525142A5 (enExample) | ||
| ES2333399T3 (es) | Metodos para tratar una leucemia. | |
| KR20030032927A (ko) | 뉴클레오시드 화합물 및 이들의 용도 | |
| RU2002101317A (ru) | Новые бициклонуклеозидные аналоги | |
| JP2015512860A5 (enExample) | ||
| TW201808981A (zh) | 用於肝臟疾病之ｄ-胺基酸化合物 | |
| KR20040018341A (ko) | 암치료용 약제 조성물 | |
| JP2004506606A (ja) | 抗ウイルスピリミジンヌクレオシド類 | |
| AU728377C (en) | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase | |
| US5756478A (en) | Method for reducing toxicity of D-nucleoside analogs with L-nucleosides | |
| JP2003532640A5 (enExample) | ||
| CA2644297A1 (en) | Prevention and treatment of cancer and other diseases | |
| US20130196938A1 (en) | Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent | |
| EP3068406B1 (en) | Mutual prodrug comprising short chain fatty acids and zebularine or 1'-cyano-cytarabine for cancer treatment | |
| RU2007104176A (ru) | Синтез и применение (-)-бета-элемена, (-)-бета-элеменала, (-)-бета-элеменола, фторида (-)-бета-элемена и их аналогов, а также промежуточных продуктов и композитов | |
| Miura et al. | Comparison of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl) cytosine with gemcitabine in its antitumor activity | |
| CN1447692A (zh) | 药物释放至肝细胞和治疗黄病毒感染的方法 | |
| ES2317913T3 (es) | Tratamiento antitumoral combinado que comprende un derivado de la distamicina sustituida por acriloilo y un antimetabolito. | |
| JP2007500205A5 (enExample) | ||
| JPWO2020243224A5 (enExample) | ||
| RU2471486C2 (ru) | Противоопухолевое средство для непрерывного внутривенного введения, содержащее цитидиновое производное | |
| RU2004116067A (ru) | Фармацевтические композиции, содержащие макролиды | |
| US8586561B2 (en) | Anti-tumor agent comprising cytidine derivative and carboplatin | |
| AU2004201676B2 (en) | Methods of treating leukemia | |
| Meadows et al. | Treatment of gastrointestinal and renal adenocarcinomas with interferon-alpha |